(NEW YORK)Shares of BioMarin Pharmaceutical Inc. advanced Friday after Wall Street reaffirmed a positive outlook that sales of the biotechnology company's genetic disorder drug Kuvan will pi...READ MORE

(NEW YORK)Shares of BioMarin Pharmaceuticals plunged Wednesday after it posted disappointing sales from its newest genetic disorder drug, Kuvan, despite a better-than-expected second-quarter...READ MORE

(NOVATO, Calif.)BioMarin Pharmaceuticals Inc. on Tuesday raised its full-year earnings estimate based on sales estimates for its products and including noncash stock compensation expenses.READ MORE

(NOVATO, Calif.)Biotech company BioMarin Pharmaceuticals Inc. said Tuesday it swung to a profit during the second quarter as net product revenue nearly tripled. Net income for the second quarter t...READ MORE

(NEW YORK)Five companies in the health care sector were added to the Russell 1000 in this year's reconstitution of the large stock index, while one stock in the sector was removed.READ MORE

Among the premarket stories for Thursday, June 12, from AP Financial News: NEW YORK (AP)--Already trading at all-time lows, shares of National CineMedia Inc. sank in premarket trad...READ MORE

(NEW YORK)A Citi Investment Research analyst said Thursday that BioMarin Pharmaceutical Inc.'s drug Kuvan may not become as popular as Wall Street expects, and she downgraded the shares ...READ MORE